Best Practices for Prophylactic Therapy in Hemophilia A

Alexis Kuhn, PharmD, BCOP, explains the benefits, risks, and potential barriers associated with prophylactic therapy for patients with hemophilia A.

Key opinion leaders discuss the factors in giving patients with hemophilia A prophylaxis, including any barriers and discussions with the patient.

A panel of experts review the goals of prophylactic therapy as well as prophylactic therapy options for patients with hemophilia A.

Robert Sidonio, Jr., MD, MSc, discusses treatment considerations and ideal candidates for factor VIII and emicizumab in patients with hemophilia A.

A panel of experts discuss the role of specialty pharmacies in managing hemophilia A as well as transitioning patients from the inpatient to outpatient care setting.

Anastasia Abramson, PharmD, MBA, reviews the dispensing process for factor VIII and emicizumab, also emphasizing the importance of patient education.

Anastasia Abramson, PharmD, MBA, outlines administration costs associated with prophylactic treatments for hemophilia A as well as other financial barriers from a specialty pharmacy perspective.

Key opinion leaders discuss how specialty pharmacies can work collaboratively to overcome both financial and nonfinancial barriers in hemophilia A.

A panel of experts share their final thoughts on the role of prophylaxis in hemophilia A and the importance of shared decision making and education.